Does vascepa's manufacturing process affect its efficacy?

Does Vascepa's manufacturing process affect its efficacy?

Vascepa contains only the ethyl ester form of eicosapentaenoic acid, or EPA. Its process begins with fish oil containing both EPA and docosahexaenoic acid, or DHA, and removes the DHA through a multi-step purification that includes distillation and chromatography. The remaining EPA ethyl ester is then encapsulated. The company reports that this method achieves at least 96 percent purity of EPA.

Why do manufacturers specify a high purity requirement?

High purity avoids interference from other fatty acids that may compete for incorporation into cell membranes or interfere with anti-inflammatory pathways. The company reports that Vascepa exceeds regulatory specifications for oxidation products and heavy metals. Oxidation products can degrade active ingredients and interfere with lipid-based drugs such as Vascepa.

How does this process compared with generic versions of icosapent ethyl?

Generic versions must demonstrate bioequivalence to the original product. Bioequivalence studies focus on rate and extent of absorption, but they do not necessarily test long-term clinical outcomes such as cardiovascular risk reduction. Some generics may use slightly different purification methods, but regulatory agencies require them to meet the gleichen purity standards.

When does Vascepa's patent expire?

Vascepa's patent on the pharmaceutical-grade purification process for high-purity EPA expires in 2030. Some countries have already issued patents to other manufacturers for similar purification methods.